CareDx Reports Fourth Quarter and FY2017 Financial Results

Genetics Investing

CareDx (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “The initial AlloSure interest and traction we experienced in the fourth quarter …

As quoted in the press release:

“The initial AlloSure interest and traction we experienced in the fourth quarter of 2017 continues in 2018,” said Peter Maag, CareDx President and Chief Executive Officer. “As of February 28, 2018, 47 centers are offering this high-value diagnostic test to kidney transplant patients across the US. Additionally, we enrolled our first patients and centers in the K-OAR registry and remain on-track to initiate 35 centers in this innovative study collecting longer-term outcome data on kidney transplant patients.”

Click here to read the full press release.

caredx diagnostic diagnostic test diagnostics diagnostics company financial results kidney transplant molecular diagnostics patients transplant Genetics Investing